Objective To review published randomised controlled trials to assess the benefit and harm of
imiquimod in the treatment of external genital warts. Data sources MEDLINE (1966 …

Genital warts caused by human papillomavirus infection are encountered commonly in
primary care. Evidence guiding treatment selection is limited, but treatment guidelines …

Objective: The purpose of this double-blind, placebo-controlled study was to evaluate the
safety, clinical efficacy and tole-rability of imiquimod (2%) in cream to cure external genital …

This review summarizes new treatments from the last seven years employed for the
treatment of genital warts caused by human papillomavirus (HPV). Imquimod 3.75% is a …

Our objective was to determine the optimal duration of treatment with imiquimod for external
genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts …

Genital human papillomavirus (HPV) infection is the most common sexually transmitted
disease. Each year 1 million new cases of genital warts are diagnosed, two thirds of which …

Objective To summarize and determine the appropriate use for the new and old
management tools for genital warts. Sources of information The following databases were …

Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are
safe and efficacious to treat anogenital warts. Methods. In two studies 534 women≥ 12 …

Genital warts are one of the most commonly reported sexually transmitted diseases
worldwide. A variety of treatment options are available but few have been assessed in large …

Background Interferon has been widely used in the treatment of genital warts for its
immunomodulatory, antiproliferative and antiviral properties. Currently, no evidence that …